These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 26090592)

  • 1. Anti-podoplanin Monoclonal Antibody LpMab-7 Detects Metastatic Lesions of Osteosarcoma.
    Kaneko MK; Oki H; Ogasawara S; Takagi M; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2015 Jun; 34(3):154-61. PubMed ID: 26090592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Monoclonal Antibody LpMab-7 Recognizing Non-PLAG Domain of Podoplanin.
    Oki H; Kaneko MK; Ogasawara S; Tsujimoto Y; Liu X; Sugawara M; Takakubo Y; Takagi M; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2015 Jun; 34(3):174-80. PubMed ID: 26090595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of monoclonal antibody LpMab-3 recognizing sialylated glycopeptide of podoplanin.
    Oki H; Ogasawara S; Kaneko MK; Takagi M; Yamauchi M; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2015 Feb; 34(1):44-50. PubMed ID: 25723283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal Antibody LpMab-9 Recognizes O-glycosylated N-Terminus of Human Podoplanin.
    Kaneko MK; Oki H; Hozumi Y; Liu X; Ogasawara S; Takagi M; Goto K; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2015 Oct; 34(5):310-7. PubMed ID: 26492618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity.
    Kato Y; Kunita A; Abe S; Ogasawara S; Fujii Y; Oki H; Fukayama M; Nishioka Y; Kaneko MK
    Oncotarget; 2015 Nov; 6(34):36003-18. PubMed ID: 26416352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.
    Kato Y; Kunita A; Fukayama M; Abe S; Nishioka Y; Uchida H; Tahara H; Yamada S; Yanaka M; Nakamura T; Saidoh N; Yoshida K; Fujii Y; Honma R; Takagi M; Ogasawara S; Murata T; Kaneko MK
    Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):20-24. PubMed ID: 28234556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of Mouse Monoclonal Antibody LpMab-13 Against Human Podoplanin.
    Ogasawara S; Kaneko MK; Honma R; Oki H; Fujii Y; Takagi M; Suzuki H; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2016 Jun; 35(3):155-62. PubMed ID: 27328060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Monoclonal Antibody LpMab-17 Developed by CasMab Technology Distinguishes Human Podoplanin from Monkey Podoplanin.
    Kato Y; Ogasawara S; Oki H; Honma R; Takagi M; Fujii Y; Nakamura T; Saidoh N; Kanno H; Umetsu M; Kamata S; Kubo H; Yamada M; Sawa Y; Morita K; Harada H; Suzuki H; Kaneko MK
    Monoclon Antib Immunodiagn Immunother; 2016 Apr; 35(2):109-16. PubMed ID: 26937552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical Analysis of Inflammatory Rheumatoid Synovial Tissues Using Anti-Human Podoplanin Monoclonal Antibody Panel.
    Suzuki T; Takakubo Y; Oki H; Liu X; Honma R; Naganuma Y; Goodman SB; Kaneko MK; Kato Y; Takagi M
    Monoclon Antib Immunodiagn Immunother; 2018 Feb; 37(1):12-19. PubMed ID: 29377768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity.
    Kaneko MK; Nakamura T; Kunita A; Fukayama M; Abe S; Nishioka Y; Yamada S; Yanaka M; Saidoh N; Yoshida K; Fujii Y; Ogasawara S; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2017 Jun; 36(3):104-112. PubMed ID: 28504613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recruitment of podoplanin positive cancer-associated fibroblasts in metastatic lymph nodes predicts poor prognosis in pathological N2 stage III lung adenocarcinoma.
    Neri S; Ishii G; Taira T; Hishida T; Yoshida J; Nishimura M; Nagai K; Ochiai A
    Ann Surg Oncol; 2012 Nov; 19(12):3953-62. PubMed ID: 22669451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Platelet C-Type Lectin-Like Receptor 2 in Promoting Lung Metastasis in Osteosarcoma.
    Ichikawa J; Ando T; Kawasaki T; Sasaki T; Shirai T; Tsukiji N; Kimura Y; Aoki K; Hayakawa K; Suzuki-Inoue K; Saitoh M; Haro H
    J Bone Miner Res; 2020 Sep; 35(9):1738-1750. PubMed ID: 32479683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LpMab-23: A Cancer-Specific Monoclonal Antibody Against Human Podoplanin.
    Yamada S; Ogasawara S; Kaneko MK; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2017 Apr; 36(2):72-76. PubMed ID: 28387591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of histological changes and changes in nm23 and c-MET expression between primary and metastatic sites in osteosarcoma: a clinicopathologic and immunohistochemical study.
    Oda Y; Naka T; Takeshita M; Iwamoto Y; Tsuneyoshi M
    Hum Pathol; 2000 Jun; 31(6):709-16. PubMed ID: 10872665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of Monoclonal Antibody LpMab-10 Recognizing Non-glycosylated PLAG1/2 Domain Including Thr34 of Human Podoplanin.
    Ogasawara S; Oki H; Kaneko MK; Hozumi Y; Liu X; Honma R; Fujii Y; Nakamura T; Goto K; Takagi M; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2015 Oct; 34(5):318-26. PubMed ID: 26492619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis.
    Sekiguchi T; Takemoto A; Takagi S; Takatori K; Sato S; Takami M; Fujita N
    Oncotarget; 2016 Jan; 7(4):3934-46. PubMed ID: 26684030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of tumour metastasis in a murine osteosarcoma model with anti-CD25 monoclonal antibody treatment.
    Kozawa E; Sugiura H; Wasa J; Kohyama K; Yamada K; Nishioka A; Nishida Y; Ishiguro N; Taguchi O
    Anticancer Res; 2010 Dec; 30(12):5019-22. PubMed ID: 21187484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin, using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN.
    Kaneko MK; Nakamura T; Honma R; Ogasawara S; Fujii Y; Abe S; Takagi M; Harada H; Suzuki H; Nishioka Y; Kato Y
    Cancer Med; 2017 Feb; 6(2):382-396. PubMed ID: 28101903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LpMab-12 Established by CasMab Technology Specifically Detects Sialylated O-Glycan on Thr52 of Platelet Aggregation-Stimulating Domain of Human Podoplanin.
    Kato Y; Ogasawara S; Oki H; Goichberg P; Honma R; Fujii Y; Kaneko MK
    PLoS One; 2016; 11(3):e0152912. PubMed ID: 27031228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin.
    Kato Y; Kaneko MK
    Sci Rep; 2014 Aug; 4():5924. PubMed ID: 25080943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.